Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Azacitidine

5 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCTHO1579

12/09/2015

A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study to Assess the Safety and Efficacy of CC -486 (Oral Azacitidine) in Combination with Pembrolizumab (MK-3475) versus Pembrolizumab plus Placebo in Subjects with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCHEM1508

08/20/2015

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Treatment

VICCHEMP14114

05/20/2015

A Phase 1, Open-label, Multicenter, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

Treatment

VICCHEM1294

02/25/2013

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission